Digestive Tract Ulcer Affecting Patents (Class 514/13.2)
-
Publication number: 20120077748Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.Type: ApplicationFiled: September 26, 2011Publication date: March 29, 2012Inventors: Sadasivan VIDYASAGAR, Paul Okunieff, Lurong Zhang
-
Publication number: 20120071412Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.Type: ApplicationFiled: November 28, 2011Publication date: March 22, 2012Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
-
Publication number: 20120071394Abstract: The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus (‘CHIPS’), the polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or a fragment or variant thereof having a biological activity of CHIPS, wherein the fragment or variant retains amino acid substitutions K40E, D42V, N77H, K100R, K105R, N111 K and/or G112A relative to the wildtype CHIPS protein of SEQ ID NO:1. In one embodiment, polypeptide consists of the amino acid sequence of SEQ ID NO: 2. Related aspects of the invention provide pharmaceutical compositions comprising a polypeptide of the invention, together with methods or making and using the same.Type: ApplicationFiled: November 30, 2009Publication date: March 22, 2012Inventors: Christina Furebring, Anna Rosén, Karin Haraldsson, Erika Gustafsson, Björn Ulrik Walse
-
Patent number: 8133580Abstract: The invention relates to an article comprising a coating, which coating comprises at least two layers, of which the inner layer is a primer layer, comprising a supporting polymer network which is composed of a supporting polymer selected from the group consisting of polyethers and polythioethers, including copolymers thereof, the supporting network optionally comprising a functional non-ionic hydrophilic polymer entangled in the supporting polymer network; and the outer layer is a functional layer comprising a functional non-ionic hydrophilic polymer and a polyelectrolyte.Type: GrantFiled: December 11, 2006Date of Patent: March 13, 2012Assignee: DSM IP Assets B.V.Inventors: Aylvin Jorge Angelo Athanasius Dias, Guido Joseph Elisabeth Hensen, Johannes Wilhelmus Belt, Marnix Rooijmans, Nicolaes Hubertus Maria De Bont, Edwin Peter Kennedy Currie
-
Patent number: 8133864Abstract: The present invention relates to a pharmaceutical composition for preventing/treating conditions associated with PAR-2. The present invention also relates to a method for preventing/treating the condition using the pharmaceutical composition and use for manufacturing the pharmaceutical composition.Type: GrantFiled: March 29, 2006Date of Patent: March 13, 2012Assignee: Kowa Company, Ltd.Inventors: Hiroyuki Ishiwata, Mototsugu Kabeya, Toru Kanke
-
Publication number: 20120021987Abstract: The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGFlike domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids.Type: ApplicationFiled: February 7, 2011Publication date: January 26, 2012Applicant: MuciMed, Inc.Inventors: Samuel B. Ho, Laurie L. Shekels
-
Publication number: 20110319317Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.Type: ApplicationFiled: March 3, 2010Publication date: December 29, 2011Applicant: OPKO CuRNA, LLCInventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
-
Publication number: 20110319330Abstract: The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes ?1-antitrypsin or an ?1-antitrypsin-like agent, including, but not limited to oxidation-resistant variants of ?1-antitrypsin, and peptoids with antitrypsin activity. The diseases treatable by the invention include cancer, autoimmune disease, sepsis neurodegenerative disease, myocardial infarction, stroke, ischemia-reperfusion injury, toxin induced liver injury and AIDS. The method of the invention is also suitable for the prevention or amelioration of diseases characterized by excessive apoptosis.Type: ApplicationFiled: April 27, 2010Publication date: December 29, 2011Applicant: BIO HOLDING, INC.Inventor: LeLand Shapiro
-
Publication number: 20110306550Abstract: Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including CNS inflammation, traumatic brain injury, inflammatory bowel disease (also known as Crohn's Disease or ulcerative colitis), cerebral ischemia, atherosclerosis, sepsis, multiple sclerosis and arthritic diseases, Alzheimer's Disease and other brain disorders. The invention encompasses methods for protecting subjects having undergone irradiation or radiotherapy by administration of ApoE or at least one ApoE mimetic peptide.Type: ApplicationFiled: April 28, 2011Publication date: December 15, 2011Applicant: Cognosci, Inc.Inventors: Michael P. VITEK, Suzanne E. MCKENNA, Christopher R. SELF
-
Publication number: 20110305634Abstract: The present invention provides compositions and methods for treating disorders associated with epithelial tissues.Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Applicant: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Publication number: 20110294736Abstract: The present invention provides a method and composition for the treatment and prevention of an autoimmune disease such a multiple sclerosis which is mediated by autoreactive T cells. The administration of a NOD-1 agonist is shown to mediate an anti-inflammatory immune response. NOD-1 agonists suitable for use in the methods and compositions of the invention include diaminopimelic acid (DAP)-containing muropeptide compounds such as Tri-DAP and M-TriDAP.Type: ApplicationFiled: December 22, 2009Publication date: December 1, 2011Applicant: THE PROVOST, FELLOWS AND SCHOLARS OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Kingston Mills, Sarah Higgins
-
Publication number: 20110258713Abstract: The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.Type: ApplicationFiled: December 23, 2009Publication date: October 20, 2011Applicant: VIVOSCRIPT, INC.Inventors: Yong Zhu, Shili Wu, Jun Bao
-
Publication number: 20110250268Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: ApplicationFiled: April 19, 2011Publication date: October 13, 2011Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
-
Publication number: 20110251126Abstract: Y4 receptor agonists which are selective for the Y4 receptor over the Y1 and Y2 receptors, are useful in the prevention and/or treatment of damage to bowel function caused by radiation therapy, radiation exposure, cytotoxic chemotherapy, inflammation, or ischemia-reperfusion of intestinal mucosa.Type: ApplicationFiled: September 11, 2009Publication date: October 13, 2011Inventors: Christian Elling, Thue Schwartz, Niels Ole Jensen, Lars-Ole Gerlach
-
Publication number: 20110245159Abstract: The present invention provides novel salts and solvates of macrocyclic compounds that bind to and/or are functional agonists of the ghrelin (growth hormone secretagogue) receptor. The invention also relates to polymorphs of these salts and solvates, pharmaceutical compositions containing these salts or solvates, and methods of using the pharmaceutical compositions. These pharmaceutical compositions are useful as therapeutics for a range of disease indications, in particular, for treatment and prevention of gastrointestinal disorders including, but not limited to, postoperative ileus, gastroparesis, including diabetic and postsurgical gastroparesis, opioid bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, functional gastrointestinal disorders and gastrointestinal dysmotility, such as that occurring in conjunction with other disease states, in critical care situations or as a result of treatment with pharmaceutical agents.Type: ApplicationFiled: September 29, 2010Publication date: October 6, 2011Inventors: Hamid R. Hoveyda, Martin Vézina, Eric Fournier, René Gagnon, Patrick Bhérer
-
Patent number: 8017576Abstract: Methods and compositions of AMP-18 derived peptides enablingly demonstrate that AMP-18 derived peptide compositions surprisingly reduce mucositis in mammals. Methods and peptide compositions treat mucositis, delays the onset or duration of mucositis, including cancer therapy-induced mucositis are disclosed. AMP 77-97 peptide derived from human AMP-18 protein alleviates cancer therapy-induced mucositis.Type: GrantFiled: May 9, 2006Date of Patent: September 13, 2011Assignee: The University of ChicagoInventor: F. Gary Toback
-
Publication number: 20110212884Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.Type: ApplicationFiled: April 20, 2010Publication date: September 1, 2011Applicant: Synergy Pharmaceuticals, Inc.Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
-
Patent number: 8008258Abstract: The present invention relates to the use of Copolymer 1 (glatiramer acetate), a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide, for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.Type: GrantFiled: January 20, 2004Date of Patent: August 30, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Rina Aharoni, Ruth Arnon, Basak Kayhan
-
Publication number: 20110207663Abstract: The invention relates to novel peptide comprising FGF-P and methods of use thereof.Type: ApplicationFiled: June 16, 2009Publication date: August 25, 2011Applicant: University of RochesterInventors: Paul Okunieff, Lurong Zhang
-
Patent number: 7993635Abstract: It is known that L-menthol controls smooth muscle contraction. In order to use L-menthol in practice as a digestive tract contraction inhibiting agent in digestive tract endoscopy, it is required to devise means of giving a formulation in which an L-menthol-containing formulation remains stable and transparent or little cloudy over a long time after the production and which shows little foaming at the administration. In the present invention, an antifoaming agent is further added to a formulation for inhibiting smooth muscle contraction or a peristaltic contraction in a digestive tract containing a L-menthol emulsion having an average particle size of less than 100 nm. Thus, it is possible to obtain a formulation that remains stable over a long time, has a high light transmittance, and produces little foam when filled into a container and sprayed at a target area to inhibit contraction to facilitate observation of the area in endoscopic examination of the digestive tract etc.Type: GrantFiled: July 27, 2009Date of Patent: August 9, 2011Assignee: Nihon Pharamaceutical Co., Ltd.Inventors: Tomonori Hamawaki, Yosuke Kataoka, Takako Isoda
-
Publication number: 20110144021Abstract: The invention refers to compositions that comprise the protein preparation, obtained from the latex of Hevea brasiliensis, in a low concentration. Additionally, the invention refers to the use of the protein preparation or the composition described herein, for the preparation of a medicine to treat chronic inflammatory diseases, and to the method of treating same that uses the aforementioned composition or the protein preparation.Type: ApplicationFiled: June 26, 2009Publication date: June 16, 2011Inventor: Fatima Mrue
-
Publication number: 20110118184Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.Type: ApplicationFiled: November 9, 2010Publication date: May 19, 2011Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer
-
Publication number: 20110104217Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: ApplicationFiled: December 14, 2010Publication date: May 5, 2011Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Galit Rotman, Michal Ayalon-Soffer
-
Publication number: 20110098223Abstract: The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.Type: ApplicationFiled: April 15, 2009Publication date: April 28, 2011Inventors: Jamal Temsamani, Claude Laruelle
-
Publication number: 20110081323Abstract: Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described.Type: ApplicationFiled: September 20, 2010Publication date: April 7, 2011Inventors: Don Kleinsek, Adriana Soto
-
Publication number: 20110077191Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.Type: ApplicationFiled: October 20, 2008Publication date: March 31, 2011Applicant: Alba Therapeutics CorporationInventor: Amir Tamiz
-
Publication number: 20110071075Abstract: A substance is described which can prevent or treat a disease associated with the secretion of an acid. A calcium receptor activator is the active ingredient in a composition which promotes bicarbonate secretion in a gastrointestinal tract. Examples of the calcium receptor activator include ?-Glu-X-Gly, wherein X represents an amino acid or an amino acid derivative, ?-Glu-Val-Y, wherein Y represents an amino acid or an amino acid derivative, ?-Glu-Ala, ?-Glu-Gly, ?-Glu-Cys, ?-Glu-Met, ?-Glu-Thr, ?-Glu-Val, ?-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, ?-Glu-Met(O), ?-Glu-?-Glu-Val, ?-Glu-Val-NH2, ?-Glu-Val-ol, ?-Glu-Ser, ?-Glu-Tau, ?-Glu-Cys(S-Me)(O), ?-Glu-Leu, ?-Glu-Ile, ?-Glu-t-Leu, and ?-Glu-Cys(S-Me).Type: ApplicationFiled: September 23, 2010Publication date: March 24, 2011Inventors: Koji Takeuchi, Eitaro Aihara, Eiji Nakamura, Tetsuo Yano, Mai Hasumura, Hisayuki Uneyama
-
Publication number: 20110059889Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: ApplicationFiled: December 18, 2009Publication date: March 10, 2011Inventors: ADAM R. MEZO, KEVIN A. MCDONNELL, CRISTINA A. TAN HEHIR, ALFREDO CASTRO
-
Publication number: 20100322948Abstract: The present invention relates to the identification and use of bone morphogenetic protein (BMP)-binding domains of members of the repulsive guidance molecule (RGM) protein family, and polypeptide fragments and fusion proteins derived therefrom. The domains, i.e., peptide fragments and fusion proteins, according to the invention are suitable as agents for the active or passive immunization of individuals, or as diagnostic and therapeutic agents for use for diseases or medical conditions in whose origin or progression a member of the RGM family and a cellular receptor associated with this molecule, such as neogenin and/or BMP in particular, is involved. The invention further relates to monoclonal and polyclonal antibodies directed against the binding domains according to the invention, and against the polypeptides derived therefrom, and to methods for producing the polypeptides, fusion proteins, and antibodies according to the invention.Type: ApplicationFiled: September 8, 2008Publication date: December 23, 2010Applicant: ABBOTT GMBH & CO. KGInventors: Bernhard Mueller, Gregor Schaffar, Axel Meyer, Martin Schmidt
-
Publication number: 20100305024Abstract: The present invention provides a method of modulating calcineurin activity in a cell by contacting the cell with at least one ApoE analog. Methods of treating various disorders associated with calcineurin activity using one or more ApoE analogs are also disclosed. In particular, the present invention provides a method of reducing demyelination and promoting remyelination in a subject. Methods of treating spinal cord or nerve injury in a subject are also described.Type: ApplicationFiled: July 31, 2008Publication date: December 2, 2010Inventors: Michael P. Vitek, Feng-Qiao Li
-
Publication number: 20100305037Abstract: The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.Type: ApplicationFiled: May 21, 2010Publication date: December 2, 2010Applicant: ALLERGAN, INC.Inventors: Michael E. Garst, Michael E. Stern
-
Publication number: 20100292151Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16” and uses thereof.Type: ApplicationFiled: November 17, 2009Publication date: November 18, 2010Applicant: ZYMOGENETICS, INC.Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
-
Publication number: 20100286024Abstract: The invention provides novel GLP-1 analogues and compositions comprising such analogues. The compounds of the invention are useful in treating diabetes mellitus and related disorders.Type: ApplicationFiled: October 27, 2006Publication date: November 11, 2010Inventor: Patrick Kanda
-
Publication number: 20100279932Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.Type: ApplicationFiled: July 12, 2010Publication date: November 4, 2010Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, PETER AMSTRONG THOMPSON
-
Publication number: 20100266579Abstract: We describe the involvement of JunD in the activation of macrophages and the association of JunD in inflammatory diseases and conditions.Type: ApplicationFiled: October 21, 2008Publication date: October 21, 2010Inventors: Terence Cook, Jacques Behmoaras, Timothy Aitman
-
Publication number: 20100266499Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: April 29, 2009Publication date: October 21, 2010Inventors: Cindy A. Sprecher, Zeren Gao, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Scott R. Presnell, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
-
Publication number: 20100240591Abstract: TPP II (tripeptidyl peptidase II) inhibitors are useful in the treatment of autoimmune and/or inflammatory diseases, for example Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Sjögrens Syndrome, Diabetes Mellitus Type I or II, Psoriasis, Eczema, Ulcerous Colitis, and Chron's Disease, or transplant rejection. Suitable compounds comprise tripeptide compounds of general formula RN1, RN2, A1, A2, A3 and RC1 are as defined herein, and which include for example the tripeptide sequences GLA and GPG.Type: ApplicationFiled: June 25, 2007Publication date: September 23, 2010Applicant: ONCOREG ABInventors: Rickard Glas, Hong Xu